Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Danielle Carter

Danielle Carter is house staff fellow, medicine liver diseases, Institute of Liver Medicine, Icahn School of Medicine at Mount Sinai, New York, United States.

Recent stories

  • Transmission Electron Micrograph view (TEM) of Hepatitis B virus

    An update on the management of chronic hepatitis B and C infectionSubscription

    9 AUG 2017

    Chronic hepatitis B and C infection are leading causes of liver-related morbidity and mortality worldwide. Current therapies for chronic hepatitis B virus (HBV) infection consisting of nucleos(t)ide analogues (NA) rarely lead to functional cure. With a better understanding of the HBV lifecycle, novel agents have been developed with the hope of achieving functional cure. The development of direct-acting antivirals (DAAs) for hepatitis C virus (HCV) therapy has led to SVR12 ra

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.